LON:INDVIndivior Share Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Indivior PLC Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add GBX 121.60 +2.60 (+2.18 %) (As of 08/14/2020 10:21 AM ET) Add Compare Share Today's Range 118.40Now: GBX 121.60▼ 124.4050-Day Range 75.05MA: GBX 100.72▼ 142.4052-Week Range 0.77Now: GBX 121.60▼ 165.80Volume1.25 million shsAverage Volume2.44 million shsMarket Capitalization£890.64 millionP/E RatioN/ADividend YieldN/ABetaN/A ProfileAnalyst RatingsChartCompetitorsInsider TradesHeadlines Indivior PLC, together with its subsidiaries, develops, manufactures, and sells buprenorphine-based prescription drugs for the treatment of opioid dependence. The company's product pipeline focuses on treating opioid use disorder, alcohol use disorder, opiate overdose, and schizophrenia. It markets and promotes SUBLOCADE injection for subcutaneous use; and SUBOXONE sublingual film, SUBOXONE sublingual tablet, and SUBUTEX sublingual tablet, as well as sells legacy analgesic products that include Temgesic, Burpex, and Buprenex. The company operates in approximately 40 countries worldwide. Indivior PLC was incorporated in 2014 and is headquartered in North Chesterfield, Virginia.Read More Beat the Market (BTM) Rank™ 2.3 Analyst's Opinion Consensus RatingIndivior has received a consensus rating of Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of GBX 142.50, Indivior has a potential upside of 17.2% from its current price of GBX 121.60.Amount of Analyst CoverageIndivior has only been the subject of 2 research reports in the past 90 days. Previous Next 3.4 Community Rank Outperform VotesIndivior has received 550 “outperform” votes. (Add your “outperform” vote.)Underperform VotesIndivior has received 269 “underperform” votes. (Add your “underperform” vote.)Community SentimentIndivior has received 67.16% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Indivior and other stocks. Vote “Outperform” if you believe INDV will outperform the S&P 500 over the long term. Vote “Underperform” if you believe INDV will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldIndivior does not currently pay a dividend.Dividend GrowthIndivior does not have a long track record of dividend growth. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Indivior insiders have not sold or bought any company stock. Previous Next 0.0 Earnings and Valuation Price to Earnings Ratio vs. the MarketThe P/E ratio of Indivior is -9.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Indivior is -9.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioIndivior has a P/B Ratio of 22.94. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 2.3Community Rank: 3.4Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.13 out of 5 stars Industry, Sector and Symbol Stock Exchange LON Industry Drugs - Generic Sub-IndustryN/A SectorMedical Current SymbolLON:INDV Previous Symbol CUSIPN/A CIKN/A Webindivior.com Phone+44-1753-217800Debt Debt-to-Equity Ratio730.77 Current Ratio1.75 Quick Ratio1.64Price-To-Earnings Trailing P/E RatioN/A Forward P/E Ratio23.59 P/E GrowthN/A Sales & Book Value Annual Sales£700 million Price / Sales1.27 Cash FlowGBX 106.46 per share Price / Cash Flow1.14 Book ValueGBX 5.30 per share Price / Book22.94Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/AMiscellaneous Employees915 Outstanding Shares732,435,968Market Cap£890.64 million Next Earnings DateN/A OptionableNot Optionable GBX 121.60 +2.60 (+2.18 %) (As of 08/14/2020 10:21 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive INDV News and Ratings via Email Sign-up to receive the latest news and ratings for INDV and its competitors with MarketBeat's FREE daily newsletter. Indivior (LON:INDV) Frequently Asked Questions How has Indivior's stock price been impacted by Coronavirus? Indivior's stock was trading at GBX 46.21 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, INDV stock has increased by 163.1% and is now trading at GBX 121.60. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Indivior? 2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Indivior in the last year. There are currently 1 hold rating and 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Indivior. What price target have analysts set for INDV? 2 Wall Street analysts have issued 1 year price objectives for Indivior's shares. Their forecasts range from GBX 85 to GBX 200. On average, they anticipate Indivior's share price to reach GBX 142.50 in the next twelve months. This suggests a possible upside of 17.2% from the stock's current price. View analysts' price targets for Indivior. Has Indivior been receiving favorable news coverage? Media coverage about INDV stock has trended positive on Friday, InfoTrie reports. The research firm rates the sentiment of news coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. Indivior earned a media sentiment score of 2.7 on InfoTrie's scale. They also gave news stories about the specialty pharmaceutical company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an impact on the company's share price in the next few days. View the latest news about Indivior. Who are some of Indivior's key competitors? Some companies that are related to Indivior include Repare Therapeutics (BLI), ABCAM PLC/ADR (ABCZY), Sorrento Therapeutics (SRNE), Reata Pharmaceuticals (RETA), BridgeBio Pharma (BBIO), GW Pharmaceuticals PLC- (GWPH), ChemoCentryx (CCXI), Dechra Pharmaceuticals (DPH), ASPEN PHARMACAR/ADR (APNHY), Evotec (EVT), EBOS Group (EBO), Momenta Pharmaceuticals (MNTA), PTC Therapeutics (PTCT), BTG (BTG) and Cronos Group (CRON). View all competitors. What other stocks do shareholders of Indivior own? Based on aggregate information from My MarketBeat watchlists, some companies that other Indivior investors own include Bigblu Broadband (BBB), Futura Medical (FUM), Directa Plus (DCTA), Lakehouse (LAKE), Aquila Services Group (AQSG), Benchmark (BMK), Bodycote (BOY), CityFibre Infrastructure (CITY), Deltex Medical Group (DEMG) and Kingfisher (KGF). Who are Indivior's key executives? Indivior's management team includes the following people: Mr. Shaun Thaxter, CEO & Exec. DirectorMr. Mark Crossley, CFO & Exec. DirectorDr. Christian Heidbreder, Chief Scientific OfficerMr. Ingo Elfering, Chief Information & Innovation OfficerMr. Jason Thompson, VP of Investor Relations What is Indivior's stock symbol? Indivior trades on the London Stock Exchange (LON) under the ticker symbol "INDV." How do I buy shares of Indivior? Shares of INDV and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock. What is Indivior's stock price today? One share of INDV stock can currently be purchased for approximately GBX 121.60. How big of a company is Indivior? Indivior has a market capitalization of £890.64 million and generates £700 million in revenue each year. Indivior employs 915 workers across the globe. What is Indivior's official website? The official website for Indivior is indivior.com. How can I contact Indivior? Indivior's mailing address is 103-105 Bath Road, SLOUGH, SL1 3UH, United Kingdom. The specialty pharmaceutical company can be reached via phone at +44-1753-217800. This page was last updated on 8/14/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
